Lior Carmon
Directeur en chef des Investissements chez Van Leer Xenia Ventures
Profil
Lior Carmon is the founder of Vaxil Bio Ltd.
which was founded in 2006, where he held the titles of CEO, Director, and Head-Research & Development.
He is currently a Director at Israel Immunological Society, Saqura Bio Ltd.
(since 2022), and Chief Investment Officer at Van Leer Xenia Ventures.
Dr. Carmon's former position was as a Director at Vaxil Bio Ltd.
Dr. Carmon holds an MBA from Ben-Gurion University of the Negev and a doctorate from Weizmann Institute of Science.
Postes actifs de Lior Carmon
| Sociétés | Poste | Début |
|---|---|---|
| Israel Immunological Society | Directeur/Membre du Conseil | - |
Van Leer Xenia Ventures
 Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Directeur en chef des Investissements | - |
Sakura Bio
 Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Directeur/Membre du Conseil | 01/10/2022 |
Anciens postes connus de Lior Carmon
| Sociétés | Poste | Fin |
|---|---|---|
| VAXIL BIO LTD. | Directeur/Membre du Conseil | 04/01/2017 |
Vaxil Bio Ltd. /Old/
 Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Directeur Général | - |
Formation de Lior Carmon
| Ben-Gurion University of the Negev | Masters Business Admin |
| Weizmann Institute of Science | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VAXIL BIO LTD. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Health Technology |
| Israel Immunological Society | |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Finance |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Health Technology |
